204 Participants Needed

Care Navigator Support for Type 2 Diabetes

(AURORA Trial)

AV
Overseen ByAmy Valdati
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Kaiser Permanente
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

The study proposes to rigorously evaluate a proactive, culturally responsive care navigator intervention targeting younger-onset Latinx individuals with a new T2D diagnosis (AURORA \[Active Outreach to Younger Latinx\]) within Kaiser Permanente Northern California (KPNC).

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

Is the Care Navigator Support for Type 2 Diabetes safe for humans?

The research does not provide specific safety data for the Care Navigator Support for Type 2 Diabetes or its related programs like AURORA Care Strategy. However, similar navigator programs have been used in healthcare settings to improve patient outcomes, suggesting they are generally considered safe.12345

What makes the AURORA Care Strategy treatment unique for managing Type 2 Diabetes?

The AURORA Care Strategy is unique because it uses patient navigators to provide culturally sensitive support and education, helping younger Latinx patients overcome barriers to healthcare access and improve diabetes management, which is not typically a focus of standard diabetes treatments.46789

What data supports the effectiveness of the AURORA Care Strategy treatment for Type 2 Diabetes?

Research shows that culturally tailored diabetes self-management education, which includes coaching and navigator programs, is effective in improving diabetes knowledge and health outcomes among Latinos. Additionally, using health information technology tools and patient navigators can help reduce healthcare disparities in this population.4591011

Who Is on the Research Team?

AG

Anjali Gopalan, MD, MS

Principal Investigator

Kaiser Permanente

Are You a Good Fit for This Trial?

This trial is for younger Latinx adults aged between 20 and 45 who are members of Kaiser Permanente Northern California, have been newly diagnosed with Type 2 Diabetes in the last 1-8 months, and have an HbA1c level of at least 8%. They must be proficient in English or Spanish. Pregnant women and individuals with Type 1 Diabetes cannot participate.

Inclusion Criteria

I am between 21 and 44 years old, recently diagnosed with Type 2 Diabetes, and my HbA1c is at least 8%.
I can communicate well in English or Spanish.

Exclusion Criteria

Pregnant women
I have Type 1 Diabetes.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the AURORA Care Strategy, including three telemedicine visits tailored to Latinx adults with early onset type 2 diabetes

3 months
3 visits (telemedicine)

Follow-up

Participants are monitored for changes in HbA1c and other diabetes-related outcomes

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • AURORA Care Strategy
Trial Overview The AURORA Care Strategy is being tested to see if a culturally responsive care navigator can help young Latinx adults manage their new diagnosis of Type 2 Diabetes more effectively within the healthcare system provided by Kaiser Permanente Northern California.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: AURORA Care StrategyExperimental Treatment1 Intervention
Group II: Usual CareActive Control1 Intervention

AURORA Care Strategy is already approved in United States for the following indications:

🇺🇸
Approved in United States as AURORA Care Strategy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kaiser Permanente

Lead Sponsor

Trials
563
Recruited
27,400,000+

Published Research Related to This Trial

A 27-week automated telephone self-management support program for diabetes significantly improved self-care behaviors and physical health scores among linguistically diverse patients, with effect sizes of 0.29 and 0.25 respectively.
The intervention was effective for English, Spanish, and Cantonese speakers, suggesting that automated telephone support can enhance diabetes management in low-income populations, although it did not significantly impact patient-centered care processes or cardiometabolic outcomes.
Diabetes health information technology innovation to improve quality of life for health plan members in urban safety net.Ratanawongsa, N., Handley, MA., Sarkar, U., et al.[2022]
Culturally tailored diabetes self-management education (DSME) effectively improves glycemic control and health outcomes in Mexican Americans, as shown in a study with 165 participants in a rural Texas community.
Adding a nurse case manager (NCM) to the DSME program increased attendance rates, although both groups showed similar improvements in diet, physical activity, and clinical outcomes, indicating the need for further research on the NCM's impact.
Integrating education, group support, and case management for diabetic Hispanics.Brown, SA., García, AA., Winter, M., et al.[2021]
Implementing volunteer bilingual navigation in a children's multispecialty clinic led to a non-significant decrease in appointment no-shows, suggesting it may help improve attendance for monolingual Spanish-speaking families.
Patient satisfaction ratings increased from 84.0 to 92.9 during the intervention, indicating that bilingual navigation could enhance the overall experience for Spanish-speaking families, even though the increase was not statistically significant.
Improving Satisfaction and Appointment Attendance Through Navigation for Spanish-Speaking Families.Flower, KB., Wurzelmann, S., Rojas, C., et al.[2021]

Citations

Diabetes health information technology innovation to improve quality of life for health plan members in urban safety net. [2022]
Integrating education, group support, and case management for diabetic Hispanics. [2021]
Improving Satisfaction and Appointment Attendance Through Navigation for Spanish-Speaking Families. [2021]
Closing the gap: eliminating health care disparities among Latinos with diabetes using health information technology tools and patient navigators. [2022]
Exploring the Relationship Between Medication Adherence and Diabetes Disparities among Hispanic Patients in a Large Health System. [2023]
Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE). [2022]
Advancing Medication Safety: Establishing a National Action Plan for Adverse Drug Event Prevention. [2019]
Latinos understanding the need for adherence in diabetes (LUNA-D): a randomized controlled trial of an integrated team-based care intervention among Latinos with diabetes. [2022]
Emergency department patient navigators successfully connect patients to care within a rapidly evolving healthcare system. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Impact of a community health workers-led structured program on blood glucose control among latinos with type 2 diabetes: the DIALBEST trial. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
A Systematic Review of Barriers to Access-to-Care in Hispanics With Type 2 Diabetes. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security